Research Analysts Set Expectations for Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Leerink Partnrs boosted their Q1 2026 earnings per share estimates for Hologic in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will earn $1.14 per share for the quarter, up from their previous estimate of $1.11. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic’s Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $1.11 EPS, Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $4.52 EPS and FY2027 earnings at $5.01 EPS.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.01 earnings per share.

Other research analysts have also issued reports about the company. Leerink Partners raised their price target on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 21st. Stephens lowered Hologic from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $78.00 to $76.00 in a research report on Wednesday, October 22nd. Morgan Stanley raised their price target on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. BTIG Research restated a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $78.00 target price on shares of Hologic in a report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, Hologic currently has an average rating of “Hold” and an average price target of $79.23.

Hologic Trading Up 0.2%

Shares of Hologic stock opened at $74.23 on Wednesday. The firm has a market capitalization of $16.51 billion, a price-to-earnings ratio of 30.80, a PEG ratio of 2.54 and a beta of 0.65. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $81.13. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The stock has a 50 day moving average of $68.70 and a 200 day moving average of $64.93.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 1.88% of the company’s stock.

Institutional Trading of Hologic

A number of institutional investors have recently bought and sold shares of HOLX. OneDigital Investment Advisors LLC lifted its holdings in Hologic by 7.9% during the 1st quarter. OneDigital Investment Advisors LLC now owns 7,247 shares of the medical equipment provider’s stock worth $448,000 after buying an additional 528 shares during the last quarter. IFM Investors Pty Ltd lifted its holdings in Hologic by 12.0% during the 1st quarter. IFM Investors Pty Ltd now owns 56,081 shares of the medical equipment provider’s stock worth $3,464,000 after buying an additional 5,996 shares during the last quarter. Penserra Capital Management LLC lifted its holdings in Hologic by 2,069.5% during the 1st quarter. Penserra Capital Management LLC now owns 13,212 shares of the medical equipment provider’s stock worth $815,000 after buying an additional 12,603 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Hologic by 4.8% during the first quarter. Crossmark Global Holdings Inc. now owns 34,137 shares of the medical equipment provider’s stock worth $2,109,000 after purchasing an additional 1,549 shares in the last quarter. Finally, Beverly Hills Private Wealth LLC increased its position in shares of Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock worth $320,000 after purchasing an additional 180 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.